Radiation therapy product developer North American Scientific (NAS) reported double-digit gains in sales numbers for its 2008 fiscal third quarter that were tempered by continuing net losses on its balance sheet.
The Chatsworth, Calif.-based firm reported revenues from continuing operations of approximately $3.4 million, a 26 percent increase over the third quarter of the prior year. The increase was attributed to a $700,000 increase in sales of NAS’ palladium brachytherapy seeds.
However, robust sales figures for the period were not able to stem a net loss from continuing operations of $4.1 million. For the same quarter in the prior fiscal year, the firm reported a net loss from continuing operations of $3 million.